First U.S. commercial procedure for Marlborough medical device

Marlborough-based CardioFocus announced Tuesday that its system for treating patients with irregular heart beats was used successfully in its first commercial U.S. procedure, marking the beginning of its commercialization in the U.S. 

 

 

 

The procedure using CardioFocus’ HeartLight Endoscopic Ablation System to treat a patient with paroxysmal atrial fibrillation was performed at The Mount Sinai Hospital in New York City on Monday, according to a press release from CardioFocus. Unlike other systems that treat atrial fibrillation, HeartLight allows specialists to see inside the heart and visually direct the application of a laser, said Burke Barrett, COO at CardioFocus. 

 

 

 

The system received premarket approval from the U.S. Food and Drug Administration in April and has been used to treat 3,700 patients worldwide, according to CardioFocus.